景瑞控股(01862.HK)料未能償還2.6億美元票據及利息1,560萬美元
景瑞控股(01862.HK)公布,公司2022年7月到期之12厘優先票據將於2022年7月25日到期。於到期時,票據未償還本金額2.6億美元及應計利息1,560萬美元將到期並應予支付。公司預計於到期時不能支付。未支付可能使其他債權人可以要求集團加快償還其債務。於公告日期,公司尚未收到集團任何債權人的任何加速到期通知。
公司已委任鐘港資本有限公司為財務顧問,以評估集團的資本結構、評估集團的流動資金及探尋所有可行解決方案以緩解當前流動資金問題,並盡快達成對所有持份者最優的解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.